vaccine against equine strangles Strangvac

Validation batches of the vaccine against equine strangles Strangvac® is completed

28 January, 2020 | General

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®. The validation production batches required for the forthcoming registration application to the European Medicines […]

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

2 January, 2020 | General

3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use. 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, and Viscofan BioEngineering, the Business Unit within the Viscofan Group), go one step further in an innovative cell therapy product. […]

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

28 November, 2019 | General

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, the UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment. 3P Biopharmaceuticals and In3Bio began their partnership in early 2019 with 3P Biopharmaceuticals being selected to […]

The manufacturing process for Strangvac, the new vaccine against equine strangles, is proceeding according to plan

27 August, 2019 | General

The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice). “We are very pleased to announce that we have now manufactured the drug substances for several million doses of Strangvac, the new vaccine […]

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder

23 July, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in the process development and GMP manufacturing of biologics announces Keensight Capital, one of the European leading players in Growth Buyout, specialist in the IT and Healthcare sectors, as its new major investor. The incorporation of this new main shareholder comes after INFARCO, […]

3P Biopharmaceuticals_Betalutin

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

26 June, 2019 | General

3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment. The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. 3P and Nordic Nanovector started their […]